OBJECTIVES: Surgical mortality and long-term outcomes are important considerations when determining strategies for multiple reoperations on the aortic valve (AV). With the rise of percutaneous valve-in-valve, we sought to evaluate the current outcomes of conventional surgery for AV reoperation, focusing first on the effect of the number of previous AV interventions with a subsequent analysis of the risk factors for adverse outcomes. RESULTS: There were 230 men and 86 women, with a median age of 58 (Q1-Q3: 46-70) years. Structural valve deterioration (SVD) of the bioprosthesis (n = 136, 44%), endocarditis (n = 57, 18%) and prosthetic valve dehiscence (n = 41, 13%) were the most common reasons for reintervention. Overall, in-hospital mortality was 7.3%: 7.2% in Group 1, 4.76% in Group 2 and 18.2% in Group 3 (P = 0.233) and ranged from 3.7% for SVD to 14.0% when endocarditis was the reason for reintervention. Higher preoperative New York Heart Association (NYHA) class (III/IV) [odds ratio (OR) 15.9, P = 0.011], injury during re-entry (OR 16.9, P = 0.015), endocarditis (OR 3.7, P = 0.038) and concomitant mitral valve replacement (OR 5.6, P = 0.006) were independent risk factors for in-hospital mortality. Survival at 8 years was 79.0 ± 3.0% for the entire cohort and 88.4 ± 3.2% for re-replacement after SVD.
INTRODUCTION
Redo-aortic valve replacement (AVR) following the first procedure can be challenging. A combination of increased life expectancy post-valvular surgery, an ageing population (particularly in Western societies) and an increasing preference for bioprosthetic valves has led to an increasing number of surgical patients presenting for redo valve replacements [1, 2] .
To date, surgical open AVR remains the gold standard for managing aortic valve (AV) disease. With a 1% incidence in the USA, AV disease can include pathologies from the stenotic valve to the regurgitant valve and rheumatic heart disease. It represents a significant health burden, particularly in the elderly population.
Currently, transcatheter valve-in-valve implantation is considered largely in patients who are at high operative risk; however, in this current paradigm of bioprosthetic structural valve deterioration (SVD), it is a management option that is gaining momentum. Indeed, a retrospective single-centre study by Erlebach et al. [3] suggested no significant difference in the 30-day mortality in patients who underwent transcatheter valve-in-valve implantation after previous open valve replacement compared with patients undergoing traditional operative redo-AVR. However, 1-year survival was significantly better in patients who underwent a redo open surgery. Moreover, when it comes to patients who are undergoing a second or a third or more AVR, it is not clear at this stage which valve substitute and which strategy would be best suited. We sought to evaluate the postoperative mortality and morbidity of patients undergoing redo-AVR for the first, second, third or more times in the last decade, with the intention of using the results to inform management decisions as patients increasingly present for redo procedures.
MATERIALS AND METHODS
This is a retrospective 10-year period study conducted between January 2007 and December 2016. We identified 316 consecutive patients at the Georges Pompidou European Hospital in Paris, France, who underwent open redo surgery on their AV. Patients were included in this study if they previously had an open surgery to their AV. Non-AV open-heart surgeries were not considered in the count of previous interventions to the AV.
The study cohort was divided into 3 groups based on the number of current reinterventions to their AV: Group 1, patients with a first redo intervention (n = 263); Group 2, patients with a second redo intervention (n = 42); and Group 3, patients with a third redo intervention or beyond (n = 11). Once a patient was included in the study, he/she was not counted again if reintervention occurred during the follow-up period, thus keeping the samples independent for statistical analysis. The study was approved by the institutional review board.
AVR in the study cohort was performed via the usual open surgical manner, reprising the median sternotomy scar from previous operations. In-hospital data were collected retrospectively from medical records. Follow-up was done through direct phone contact with the referring cardiologist and the patient. Mean follow-up period at the completion of the study was 60 ± 30 months (calculation of means made with censoring deceased patients at the time of death).
Statistical analysis
Descriptive statistics were expressed as median and 25-75% quartiles [median (Q1-Q3)] for continuous variables and numbers (proportions) for categorical variables. To identify the significant differences in preoperative and intraoperative categorical data and 30-day mortality between groups, a v 2 test was used, except when the expected contingent cell in cross-tabulation was <5, in which case a Fisher's exact test was preferred. One-way analysis of variance or non-parametric Kruskal-Wallis test was also used for differences in continuous data, depending on the normality distribution of the variables within groups. Estimates for longterm survival and recurrence of any type of AV reintervention (including percutaneous procedures) were made using the Kaplan-Meier method. Considering the total study cohort, preoperative data of the patients were then entered into a stepwise binary logistic regression analysis to identify the independent predictors for in-hospital mortality. The appropriateness of the tested variables was first determined by univariable analysis using the v 2 or Fisher's exact test for categorical data and the Student's t-test for continuous data with a P-value <0.2.
The log-rank test was used to determine univariable predictive factors of survival. Each variable with a P-value <0.2 was entered into a Cox proportional hazard regression multivariable analysis with a backward stepwise selection process to identify the independent multivariable predictive factors of long-term mortality. Statistical analyses were performed using IBM SPSS Statistics v22 software (IBM Corp, Armonk, NY, USA).
RESULTS
There were 230 men and 86 women with a median age of 58 (46-70) years. Baseline characteristics of the 3 groups based on the number of AV reinterventions are listed in Table 1 . Compared with Group 3, patients in Group 1 had a lower mean systolic pulmonary arterial pressure and a higher mean left ventricular ejection fraction. Reasons for reintervention were SVD in 43.0% (n = 136), AV endocarditis in 18.0% (n = 57), prosthetic valve dehiscence (PVD) in 13.0% (n = 41), recurrent AV disease after previous valve repairs in 11 .1% (n = 35), mechanical valve dysfunction in 8.9% (n = 28) and redo-Bentall procedure for aortic aneurysm in 6.0% (n = 19). Details of the reasons for reintervention in each group are shown in Fig. 1 .
Intraoperative characteristics
Descriptive data regarding surgical procedures specific for each group are listed in Table 2 . All patients underwent an AV replacement. A total of 192 (60.8%) patients underwent one or more concomitant procedures, with 29 (9.3%) patients undergoing tricuspid valve repair or replacement, 38 (12.3%) a mitral valve replacement (MVR), 38 (12.0%) a replacement of the ascending aorta and 49 (15.5%) a redo-Bentall procedure. Concomitant coronary artery bypass grafting was also performed in 18 (5.7%) patients.
A total of 6 re-entry injuries (1.9%) occurred, involving the thoracic aorta (n = 4), the superior vena cava (n = 1) and the right atrium (n = 1). The latter 2 were fatal.
Immediate postoperative outcomes
Postoperative outcomes are shown in Fig. 2 . Overall hospital mortality was 7.3% (7.2% in Group 1, 4.76% in Group 2 and 18.18% in Group 3; P = 0.233, Fisher's exact test). Low cardiac output syndrome, defined as inotropic requirement over 48 h to maintain a systolic arterial pressure above 90 mmHg, differed between groups, being far more frequent in Group 3 compared with Groups 1 and 2 (P = 0.04, v 2 test). In addition to ionotropic support, 15 patients with low cardiac output syndrome were treated with intra-aortic balloon pump and 3 with extracorporeal membrane oxygenation. A total of 23 surgical revisions were performed for excessive bleeding (7.3%).
Long-term follow-up
Global survival rate at 8 years was 79.0 ± 3.0%. Based on the number of previous AV interventions, survival rates at 8 years were 79.6 ± 3.3% in Group 1, 80.3 ± 9.0% in Group 2 and 50.4% ± 10.1% in Group 3, respectively (Fig. 3) .
Recurrence of any new AV procedure at 8 years was 86.7 ± 3.4%, 89.8 ± 2.6% in Group 1 and 84.1 ± 6.7% in Group 2 (log-rank test, P = 0.198). None of the Group 3 patients were reoperated on AV during follow-up. Based on the initial reason for reintervention, recurrence of any new AV procedure at 8 years was 97.8 ± 1.8% for SVD, 80.9 ± 10.0 for redo-Bentall procedure, 81.8 ± 7.9 for endocarditis, 68.2 ± 14% for PVD, 86.9 ± 6.2% for AV disease after previous valve repair and 76.5 ± 17.4 for mechanical valve dysfunction (log-rank test, P = 0.032).
Survival at 8 years after AV re-replacement for SVD of a bioprosthesis was 88.4% ± 3.2%. There was no statistical difference in long-term survival between patients receiving a bioprosthesis or a mechanical valve (survival rates were 76.6 ± 4.6% and 81.7 ± 4.0% at 8 years, respectively, log-rank test, P = 0.425).
Multivariable predictors of in-hospital and longterm outcomes
Based on the reason for current reintervention, in-hospital mortality was 3.7% for SVD, 5.3% for redo-Bentall's procedure, 5.7% for AV disease after previous valve repair, 9 .8% for PVD, 10.7% for mechanical valve dysfunction and 14.0% for endocarditis. Considering the whole cohort by multivariable analysis, risk factors associated with overall in-hospital mortality are presented in Table 3 . The area under the curve for the receiver operating characteristics of EuroSCORE II and Society of Thoracic Surgeons (STS) mortality score as predictors of surgical mortality were 0.830 (0.757-0.904) and 0.826 (0.742-0.910), respectively (Fig. 4) .
In Cox multivariable regression analysis, preoperative New York Heart Association (NYHA) Class III/IV, concomitant MVR and PVD were independent factors affecting long-term survival (Table 4) .
DISCUSSION
Currently, as the number of heart operations increases, multiple redo valve surgeries are becoming increasingly common. In a large series of patients with various reasons for reintervention, we demonstrated that outcomes of redo-AV surgery were more influenced by preoperative characteristics such as symptoms at presentation, aetiology and the need for concomitant MV surgery than the number of sternal re-entries.
Our overall operative mortality results were in accordance with previous reports by Akins et al. [4] and Jones et al. [5] . Groups 1 and 2, representing patients undergoing redo-and reredo-AV interventions, respectively, shared a similar aetiological pattern. They also had similar complication rates and outcomes. Therefore, a second redo procedure on the AV did not appear to increase morbidity compared with a single redo procedure with respect to the reason for reintervention. Similar findings have been reported by Tyers et al. [6] and recently by Davierwala et al. [7] . We also found that patients undergoing a fourth or more AV intervention (Group 3) seemed to have a higher allcomplications rate but the limited number of patients in this group restricts any comparison with the other 2 groups. Moreover, patients in Group 3 were often referred late to surgery with more altered LV functions and higher pulmonary pressures at presentation.
One of the major concerns regarding cardiac reinterventions is injury at resternotomy. Our incidence of re-entry injury was smaller than those reported by Roselli et al. [8] or Ellman et al. [9] . As recommended by Morishita et al. [10] , a systematic preoperative investigation by a computed tomography scan in our patients who had previously undergone aortic surgery or coronary artery bypass grafting was certainly helpful in localizing the potential hazards during dissection and assessing the spatial relationship between the inner aspect of the sternum and the underlying mediastinal, cardiac and vascular structures. Nevertheless, as described previously by these authors, we found that the number of re-entry injuries was influenced by the number of re-sternotomies and had an impact on operative mortality. The presence of patent internal thoracic artery grafts may also compromise optimal myocardial protection if not controlled and has been assigned as an independent risk factor for injury by Park et al. [11] in an analysis of more than 2500 cardiac reinterventions. When the internal thoracic artery was considered impossible to be controlled, the so-called 'open internal thoracic artery' technique described by Vistarini et al. [12] has been used for years by some of the surgeons of our department with good results. There were no injuries to the coronary grafts reported in our study cohort. Furthermore, as already reported by Khaladj et al. [13] , the presence of previous coronary artery bypass grafting was not related to adverse outcomes.
Combined MVR, as opposed to mitral valve repair, has been known to negatively affect mortality and morbidity during AVR [14, 15] . Our results confirmed this established fact in redo-AV surgery. Furthermore, we found that concomitant MVR was also a risk factor for long-term mortality. In contrast, classical combined procedures such as aortic root replacement, coronary artery bypass grafting (described earlier) or tricuspid valve surgery were not associated with increased mortality in our study. The risk related to the latter procedure certainly may have benefitted from the large proportion of prophylactic tricuspid annuloplasties performed in our department, based more on the annular diameter rather than the dysfunction severity of the tricuspid valve.
Although non-elective surgery was not associated with increased in-hospital mortality in our study, we found that urgency remained frequent in the population undergoing AV reinterventions. In addition, more than one-third of our patients presented with severe preoperative dyspnoea, which was an independent risk factor for operative mortality and affected longterm prognosis. This appeals for earlier timing, whenever possible, in addressing patients who require AV reintervention, as already advocated by Vogt et al. [16] , almost 20 years ago.
The various causes for reintervention in our analysis showcased very disparate postoperative course profiles. For endocarditis, which exclusively appeared on prosthetic valves, we reported an in-hospital mortality rate as high as 14% and an odds ratio of 3.66. This result was rationally lower than most of the other mortality rates reported in the literature [17, 18] but confirms that aortic prosthetic valve endocarditis is a serious disease, for which surgery remains challenging. Although we did not demonstrate a real statistical significance, it may also have had an influence on long-term prognosis.
In our experience, PVD accounted for 12.6% of the cases for AV reintervention and the proportion appeared to increase with the number of reoperations. Although defined as a classical complication after AV replacement, occurrence of non-infectious PVD has been reduced to 2.2% in a recent report by Duncan et al. [19] . However, in terms of surgical mortality, PVD remains associated with a 10% mortality rate that confirmed the results recently published by Taramasso et al. [20] . Moreover, our data demonstrated that PVD was an independent risk factor for longterm all-cause mortality. Thus, we believe that alternative approaches such as transcatheter closure using vascular plugs should be considered in this setting, as early results are encouraging.
In comparison, SVD, the leading cause for reintervention in this study, was associated with excellent short-and long-term outcomes. Our data confirmed the general trend towards a reduction of mortality in patients requiring AV reintervention for SVD [21] . This has mainly 2 implications: first, it could serve as a benchmark to compare with transcatheter valve-in valve therapy, which has recently been shown to have some drawbacks. Indeed, the recent retrospective analysis of the Global Valve-in-Valve Registry from Dvir et al. [22] has shown a 15.3% rate of valve malposition and a 3.5% rate of ostial obstruction complications that are rare in open redo-AVR. A single-centre Canadian study also demonstrated that patients receiving a valve-in-valve procedure following bioprosthetic SVD had a lower survival at 1 year [3] . Therefore, particularly in a younger population, transcatheter aortic valve implantation may not be a suitable option for SVD at the moment. Secondly, our results regarding redo-AVR for SVD may have an implication on the choice of prosthetic valve. Indeed, the main factors in making this choice include the risk of anticoagulation, thromboembolism and bleeding events that could occur with mechanical valves, whereas bioprosthetic valves are not as durable and thus have a risk of SVD leading to reintervention [23, 24] . In fact, a recent study by Glaser et al. [25] noted that patients between 50 and 69 years undergoing the first ever intervention to their AV and who opted for a bioprosthetic valve had a significantly higher risk of reintervention compared to those opting for a mechanical AV (hazard ratio 2.36). Thus, at present, mechanical valves are usually offered to patients younger than 60 years [26] . However, Ruel et al. [27] have demonstrated that selection of bioprosthetic valves in patients below 60 years of age had no impact on 30-year survival. Furthermore, our data suggested that the first and second AV reinterventions for SVD have a similar low operative risk, close to the initial AVR surgical procedure [28] . This is in line with Spampinato et al. [29] who suggested, 20 years ago, that the choice of a bioprosthetic valve for a redo surgery following SVD was not hazardous.
Limitations
The limitations of this study include its inherent retrospective design and analysis of observational data. Furthermore, the groups do not comprise a similar number of patients, particularly Group 3, with 11 patients over 10 years compared with 263 and 42 in Groups 1 and 2, respectively. However, this would be reflective of true clinical practice as it is not common to have patients presenting for a third or more redo-AVRs, and a much longer, and larger, study incorporating more than one facility is possibly required to obtain higher numbers. Finally, the Cardiac STS Score could not be utilized for those undergoing concomitant AVR and mitral valve procedures, and for this reason, the EuroSCORE II was also used; perhaps future models of prediction could incorporate this.
CONCLUSIONS
Multiple AV reinterventions carry an acceptable risk of inhospital mortality, especially in the setting of isolated AVR for SVD of a bioprosthetic valve. These findings may favour the use of a biological valve substitute for AVR in young patients. Furthermore, they could serve as a benchmark for defining the role of valve-in-valve implantation in the setting of multiple AV reinterventions, which is still unknown. Given the inherently higher risks of AV reintervention associated with the transcatheter approaches, the latter may be considered more selectively in older patients with high preoperative risk well assessed by the EuroSCORE II and STS mortality scores.
